Article
Biochemistry & Molecular Biology
Meina Wang, Roy S. Herbst, Chris Boshoff
Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.
Article
Clinical Neurology
Assaf Berger, Reed Mullen, Kenneth Bernstein, Juan Diego Alzate, Joshua S. Silverman, Erik P. Sulman, Bernadine R. Donahue, Abraham Chachoua, Elaine Shum, Vamsidhar Velcheti, Joshua Sabari, John G. Golfinos, Douglas Kondziolka
Summary: This study explored the possibility of extended survival in patients with non-small-cell lung cancer (NSCLC) brain metastases in the current era. The results showed that factors associated with increased survival included age <65 years, higher KPS value, absence of extracranial metastases, fewer brain metastases, and targeted therapy.
Article
Oncology
Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh, David R. Spigel, Edward B. Garon, Meghan E. Bushway, Asaf Poran, Joong Hyuk Sheen, Victoria Kohler, Ekaterina Esaulova, John Srouji, Suchitra Ramesh, Rohit Vyasamneni, Binisha Karki, Tracey E. Sciuto, Himanshu Sethi, Jesse Z. Dong, Melissa A. Moles, Kelledy Manson, Michael S. Rooney, Zakaria S. Khondker, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan
Summary: Neoantigens derived from tumor DNA mutations can be targeted for immune-based therapy. This study presents the clinical and immune data from a Phase lb clinical trial investigating a personalized neoantigen vaccine NEO-PV-01 in combination with other drugs for first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC). The analysis of 38 patients showed that this regimen is safe and has immunogenicity.
Review
Oncology
Huaiyu Wang, Xuning Wang, Suxin Jiang, Jingna Zhu, Jie Liu, Chuanhong Zhou, Yanjun Zhu, Yong Han
Summary: This case report presents a 50-year-old female patient diagnosed with small cell lung cancer (SCLC) with multiple brain and spinal metastases. The patient benefited from treatment with anlotinib combined with immunotherapy after experiencing disease progression. Additionally, the study highlights the application of ctDNA dynamic monitoring in the treatment process.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
M. Jongbloed, V. Bartolomeo, M. Steens, S. Dursun, T. van de Lisdonk, D. K. M. De Ruysscher, L. E. L. Hendriks
Summary: The standard first-line treatment for non-oncogene driven metastatic NSCLC is an immune checkpoint inhibitor-based strategy. Adding local radical treatment to patients with synchronous oligometastatic NSCLC responding to systemic therapy is recommended. This study compares the outcomes of patients treated with induction-ICI and chemotherapy to those treated with chemotherapy only, with or without LRT, and suggests that ICI-based systemic treatment may result in superior survival outcomes.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Wenxiao Jiang, Guiqing Cai, Peter Hu, Yue Wang
Summary: Non-small cell lung cancer is recognized as one of the deadliest cancers globally, driven by smoking and air pollution. With the advancement of personalized medicine, physicians are increasingly aware of how to more effectively use anti-cancer agents.
ACTA PHARMACEUTICA SINICA B
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yang Ni, Guanghui Huang, Xia Yang, Xin Ye, Xiaoguang Li, Qingliang Feng, Yongjie Li, Wenhong Li, Jiao Wang, Xiaoying Han, Min Meng, Zhigeng Zou, Zhigang Wei
Summary: This study demonstrates that microwave ablation is a safe, effective, and potentially curative therapy for medically inoperable stage I non-small cell lung cancer patients. The five-year follow-up shows high disease-free survival and overall survival rates.
EUROPEAN RADIOLOGY
(2022)
Review
Oncology
Robert Briski, Justin Taylor
Summary: Though rare, Richter Transformation (RT) is a serious complication of chronic lymphocytic leukemia. RT carries a high mortality rate and represents an unmet clinical need. With an improved understanding of its molecular biology, there is hope that novel targeted therapies and immunotherapies will lead to improved outcomes in this disease.
Article
Clinical Neurology
Yu Wang, Jing Li, Tao Liu, Mengxi Ge, Xiaoyu Ji, Zhaohui Chu, Qiong Zhan, Xiaohua Liang, Xinli Zhou
Summary: This study investigated treatment strategies and clinical outcomes in patients with non-small-cell lung cancer (NSCLC) and leptomeningeal metastasis (LM). The findings showed that the use of third-generation tyrosine kinase inhibitors (TKIs) significantly improved LM progression-free survival (LMPFS) and overall survival (OS) in NSCLC patients with EGFR T790M mutation. Better Eastern Cooperative Oncology Group performance status, EGFR exon 19del, and clinical improvement of LM after therapy were independently associated with better OS.
WORLD NEUROSURGERY
(2023)
Article
Oncology
Celion Tang, Hitesh Mistry, Neil Bayman, Clara Chan, David Cobben, Corinne Faivre-Finn, Margaret Harris, Jason Kennedy, Laura Pemberton, Gareth Price, Hamid Sheikh, David Woolf, Joanna Coote, Ahmed Salem
Summary: The outcomes of NSCLC patients with COPD and ILD treated with curative-intent radiotherapy were retrospectively investigated. Poor overall survival was correlated with the presence of ILD, but not with decreased forced expiratory volume in 1-second. Increased breathlessness and oxygen requirements after radiotherapy were observed in severe/very severe COPD and ILD patients.
RADIOTHERAPY AND ONCOLOGY
(2021)
Review
Oncology
Wei-Ke Kuo, Ching-Fu Weng, Yin-Ju Lien
Summary: This study provides evidence supporting the use of treatment beyond progression (TBP) for non-small cell lung cancer (NSCLC), showing significant advantages in post-progression progression-free survival, post-progression overall survival, and overall survival from the initiation of drugs. However, further large, randomized, controlled trials are needed to investigate the efficacy of TBP in lung cancer treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Bin Yang, Chengxing Liu, Ren Wu, Jing Zhong, Ang Li, Lu Ma, Jian Zhong, Saisai Yin, Changsheng Zhou, Yingqian Ge, Xinwei Tao, Longjiang Zhang, Guangming Lu
Summary: A DeepSurv nomogram based on radiomic features and clinicopathological factors was developed and validated, which showed good predictive performance for overall survival in patients with non-small cell lung cancer and could guide personalized adjuvant chemotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Brendan T. Heiden, Daniel B. Eaton, Kathryn E. Engelhardt, Su-Hsin Chang, Yan Yan, Mayank R. Patel, Daniel Kreisel, Ruben G. Nava, Bryan F. Meyers, Benjamin D. Kozower, Varun Puri
Summary: This study found that surgical procedures delayed more than 12 weeks were associated with increased risk of recurrence and worse survival in patients with clinical stage I NSCLC, suggesting that timely treatment is crucial for better outcomes.
Article
Multidisciplinary Sciences
Qing Li, Zhen Lin, Ye Hong, Yang Fu, Yueyun Chen, Ting Liu, Yue Zheng, Jiangfang Tian, Chunhua Liu, Wei Pu, Zhenyu Ding, Chun Wang
Summary: Patients with advanced non-small cell lung cancer are susceptible to brain metastases, including brain parenchymal metastases and leptomeningeal metastases. Patients with leptomeningeal metastases have a higher proportion of EGFR exon 21 point mutations and shorter survival compared to patients without brain metastases or with brain parenchymal metastases. Two prediction models were developed to predict the development of brain parenchymal metastases and leptomeningeal metastases in advanced non-small cell lung cancer patients.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Helen Sadik, Daryl Pritchard, Derry-Mae Keeling, Frank Policht, Peter Riccelli, Gretta Stone, Kira Finkel, Jeff Schreier, Susanne Munksted
Summary: Many patients with cancer are unable to receive the most effective personalized treatments due to challenges in integrating predictive biomarker testing into clinical care. Clinical practice gaps, such as operational inefficiencies and inappropriate testing result usage, contribute to the loss of patients along the precision oncology pathway. This study analyzed the impact of these gaps on the treatment of advanced non-small-cell lung cancer (aNSCLC), revealing that a significant percentage of eligible patients do not benefit from precision oncology therapies.
JCO PRECISION ONCOLOGY
(2022)
